Improvement in Neuropathy Specific Quality of Life in Patients with Diabetes after Vitamin D Supplementation

Uazman Alam, Asher Fawwad, Fariha Shaheen, Bilal Tahir, Abdul Basit, Rayaz A Malik, Uazman Alam, Asher Fawwad, Fariha Shaheen, Bilal Tahir, Abdul Basit, Rayaz A Malik

Abstract

Objective: To assess the effect of vitamin D supplementation on neuropathy specific quality of life (NeuroQoL) in patients with painful diabetic neuropathy.

Methods: This prospective, open label study was conducted between June 2012 and April 2013. Patients with symptomatic diabetic neuropathy were given a single dose of 600,000 IU intramuscular vitamin D, and NeuroQol was assessed at baseline and at five follow-up visits every 4 weeks.

Results: Of 143 participants, 41.3% were vitamin D deficient (vitamin D < 20 ng/ml). Treatment with vitamin D resulted in a significant increase in 25(OH)D (P < 0.0001) and a significant improvement in the NeuroQoL subscale score for emotional distress (P = 0.04), with no significant change in the other NeuroQoL domains of painful symptoms and paresthesia, loss of temperature and touch sensation, unsteadiness, limitation in daily activities, and interpersonal problems. There was a significant reduction in patient perception about foot problems on QoL of "quite a lot" (P < 0.05) and "very much" (P < 0.0001) with a significant reduction in the baseline response of having a "poor" QoL from 5.2% to 0.7% (P < 0.0001) and an increase in the response of an "excellent QoL" from 1.5% to 7.4% (P < 0.0001).

Conclusion: Vitamin D is effective in improving quality of life in patients with painful diabetic neuropathy.

Figures

Figure 1
Figure 1
(a) Comparison of baseline and posttreatment patient's perception on QoL. (b) Comparison of baseline and post treatment general classification on QoL. ∗P < 0.05, ∗∗P < 0.0001.

References

    1. Sadosky A., Schaefer C., Mann R., et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2013;6:79–92. doi: 10.2147/DMSO.S37415.
    1. Abbott C. A., Malik R. A., van Ross E. R. E., Kulkarni J., Boulton A. J. M. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34(10):2220–2224. doi: 10.2337/dc11-1108.
    1. Celikbilek A., Gocmen A. Y., Tanik N., et al. Decreased serum vitamin D levels are associated with diabetic peripheral neuropathy in a rural area of Turkey. Acta Neurologica Belgica. 2015;115(1):47–52. doi: 10.1007/s13760-014-0304-0.
    1. Wang D. D., Bakhotmah B. A., FB H., Alzahrani H. A. Prevalence and correlates of diabetic peripheral neuropathy in a Saudi Arabic population: a cross-sectional study. PLoS One. 2014;9(9, article e106935) doi: 10.1371/journal.pone.0106935.
    1. Ali A., Iqbal F., Taj A., Iqbal Z., Amin M. J., Iqbal Q. Z. Prevalence of microvascular complications in newly diagnosed patients with type 2 diabetes. Pakistan Journal of Medical Sciences. 2013;29(4):899–902. doi: 10.12669/pjms.294.3704.
    1. Alam U., Najam O., Al-Himdani S., et al. Marked vitamin D deficiency in patients with diabetes in the UK: ethnic and seasonal differences and an association with dyslipidaemia. Diabetic Medicine. 2012;29(10):1343–1345. doi: 10.1111/j.1464-5491.2012.03692.x.
    1. Arabi A., El Rassi R., El-Hajj Fuleihan G. Hypovitaminosis D in developing countries—prevalence, risk factors and outcomes. Nature Reviews Endocrinology. 2010;6(10):550–561. doi: 10.1038/nrendo.2010.146.
    1. Jawaid S. A., Jawaid M. Management of diabetic foot ulcers: some bitter facts and harsh realities. Pakistan Journal of Medical Sciences. 2006;22:97–100.
    1. Sheikh A., Saeed Z., Jafri S. A. D., Yazdani I., Hussain S. A. Vitamin D levels in asymptomatic adults-a population survey in Karachi, Pakistan. PLoS One. 2012;7(3, article e33452) doi: 10.1371/journal.pone.0033452.
    1. Shehab D., Al-Jarallah K., Abdella N., Mojiminiyi O. A., Al Mohamedy H. Prospective evaluation of the effect of short-term oral vitamin D supplementation on peripheral neuropathy in type 2 diabetes mellitus. Medical Principles and Practice. 2015;24(3):250–256. doi: 10.1159/000375304.
    1. Soderstrom L. H., Johnson S. P., Diaz V. A., Mainous A. G., 3rd Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001-2004 NHANES. Diabetic Medicine. 2012;29(1):50–55. doi: 10.1111/j.1464-5491.2011.03379.x.
    1. Skalli S., Muller M., Pradines S., Halimi S., Wion-Barbot N. Vitamin D deficiency and peripheral diabetic neuropathy. European Journal of Internal Medicine. 2012;23(2):e67–e68. doi: 10.1016/j.ejim.2011.11.008.
    1. Alam U., Arul-Devah V., Javed S., Malik R. A. Vitamin D and diabetic complications: true or false prophet? Diabetes Therapy. 2016;7(1):11–26. doi: 10.1007/s13300-016-0159-x.
    1. Alam U., Amjad Y., Chan A. W., Asghar O., Petropoulos I. N., Malik R. A. Vitamin D deficiency is not associated with diabetic retinopathy or maculopathy. Journal of Diabetes Research. 2016;2016:7. doi: 10.1155/2016/6156217.6156217
    1. Shehab D., Al-Jarallah K., Mojiminiyi O. A., Al Mohamedy H., Abdella N. A. Does vitamin D deficiency play a role in peripheral neuropathy in type 2 diabetes? Diabetic Medicine. 2012;29(1):43–49. doi: 10.1111/j.1464-5491.2011.03510.x.
    1. Lv W. S., Zhao W. J., Gong S. L., et al. Serum 25-hydroxyvitamin D levels and peripheral neuropathy in patients with type 2 diabetes: a systematic review and meta-analysis. Journal of Endocrinological Investigation. 2015;38(5):513–518. doi: 10.1007/s40618-014-0210-6.
    1. He R., Hu Y., Zeng H., et al. Vitamin D deficiency increases the risk of peripheral neuropathy in Chinese patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews. 2017;33(2, article e2820) doi: 10.1002/dmrr.2820.
    1. Basit A., Basit K. A., Fawwad A., et al. Vitamin D for the treatment of painful diabetic neuropathy. BMJ Open Diabetes Research & Care. 2016;4(1, article e000148) doi: 10.1136/bmjdrc-2015-000148.
    1. Rubin R. R., Peyrot M. Quality of life and diabetes. Diabetes/Metabolism Research and Reviews. 1999;15(3):205–218. doi: 10.1002/(SICI)1520-7560(199905/06)15:3<205::AID-DMRR29>;2-O.
    1. Benbow S. J., Wallymahmed M. E., MacFarlane I. A. Diabetic peripheral neuropathy and quality of life. QJM: An International Journal of Medicine. 1998;91(11):733–737. doi: 10.1093/qjmed/91.11.733.
    1. Moore A., Wiffen P., Kalso E. Antiepileptic drugs for neuropathic pain and fibromyalgia. JAMA. 2014;312(2):182–183. doi: 10.1001/jama.2014.6336.
    1. Backonja M., Beydoun A., Edwards K. R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831–1836. doi: 10.1001/jama.280.21.1831.
    1. Boyle J., Eriksson M. E. V., Gribble L., et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012;35(12):2451–2458. doi: 10.2337/dc12-0656.
    1. Vileikyte L., Peyrot M., Bundy C., et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care. 2003;26(9):2549–2555. doi: 10.2337/diacare.26.9.2549.
    1. Smith S. C., Lamping D. L., Maclaine G. D. H. Measuring health-related quality of life in diabetic peripheral neuropathy: a systematic review. Diabetes Research and Clinical Practice. 2012;96(3):261–270. doi: 10.1016/j.diabres.2011.11.013.
    1. Bondor C. I., Veresiu I. A., Florea B., Vinik E. J., Vinik A. I., Gavan N. A. Epidemiology of diabetic foot ulcers and amputations in Romania: results of a cross-sectional quality of life questionnaire based survey. Journal of Diabetes Research. 2016;2016:7. doi: 10.1155/2016/5439521.5439521
    1. Galer B. S., Gianas A., Jensen M. P. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Research and Clinical Practice. 2000;47(2):123–128. doi: 10.1016/S0168-8227(99)00112-6.
    1. Vinik A., Emir B., Cheung R., Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clinical Therapeutics. 2013;35(5):612–623. doi: 10.1016/j.clinthera.2013.03.008.
    1. Veresiu A. I., Bondor C. I., Florea B., Vinik E. J., Vinik A. I., Gavan N. A. Detection of undisclosed neuropathy and assessment of its impact on quality of life: a survey in 25,000 Romanian patients with diabetes. Journal of Diabetes and its Complications. 2015;29(5):644–649. doi: 10.1016/j.jdiacomp.2015.04.001.
    1. Vileikyte L., Leventhal H., Gonzalez J. S., et al. Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care. 2005;28(10):2378–2383. doi: 10.2337/diacare.28.10.2378.
    1. Boyd A., Casselini C., Vinik E., Vinik A. Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate. Journal of Diabetes Science and Technology. 2011;5(3):714–722. doi: 10.1177/193229681100500326.
    1. Boyle J., Eriksson M. E. V., Gribble L., et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012;35(12):2451–2458. doi: 10.2337/dc12-0656.
    1. Marchettini P., Wilhelm S., Petto H., et al. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy? European Journal of Pain. 2016;20(3):472–482. doi: 10.1002/ejp.763.
    1. Huang W., Shah S., Long Q., Crankshaw A. K., Tangpricha V. Improvement of pain, sleep, and quality of life in chronic pain patients with vitamin D supplementation. The Clinical Journal of Pain. 2013;29(4):341–347. doi: 10.1097/AJP.0b013e318255655d.
    1. Lee P., Chen R. Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. Archives of Internal Medicine. 2008;168(7):771–772. doi: 10.1001/archinte.168.7.771.
    1. Van Acker K., Bouhassira D., De Bacquer D., et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes & Metabolism. 2009;35(3):206–213. doi: 10.1016/j.diabet.2008.11.004.
    1. Humble M. B. Vitamin D, light and mental health. Journal of Photochemistry and Photobiology B: Biology. 2010;101(2):142–149. doi: 10.1016/j.jphotobiol.2010.08.003.
    1. Gore M., Brandenburg N. A., Dukes E., Hoffman D. L., Tai K.-S., Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. Journal of Pain and Symptom Management. 2005;30(4):374–385. doi: 10.1016/j.jpainsymman.2005.04.009.
    1. Almurdhi M. M., Reeves N. D., Bowling F. L., Boulton A. J., Jeziorska M., Malik R. A. Reduced lower-limb muscle strength and volume in patients with type 2 diabetes in relation to neuropathy, intramuscular fat, and vitamin D levels. Diabetes Care. 2016;39(3):441–447. doi: 10.2337/dc15-0995.
    1. Alam U., Chan A. W., Buazon A., et al. Differential effects of different vitamin D replacement strategies in patients with diabetes. Journal of Diabetes and its Complications. 2014;28(1):66–70. doi: 10.1016/j.jdiacomp.2013.09.003.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다